ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "B cells"

  • 2018 American Transplant Congress

    Combination Proteasome Inhibition and Anti-BAFF Therapy Permits Highly Sensitized Rhesus Kidney Transplantation

    B. Ezekian, J. Kwun, M. Manook, P. Schroder, J. Yoon, M. Mulvihill, K. Freischlag, J. Park, J. Cochran, K. Kroning, J. Yi, S. Knechtle.

    Duke Transplant Center, Duke University Medical Center, Durham, NC.

    Purpose:HLA-sensitization is a significant immunologic barrier to successful kidney transplantation (KT). We have shown that proteasome inhibition (PI) in insolation reduces plasma cells (PCs), but…
  • 2018 American Transplant Congress

    B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression

    Q. Gao,1 A. Mehta,2 A. Guasch,2 A. Ghali,2 A. Kirk,1 H. Xu.1

    1Department of Surgery, Duke University Medical Center, Durham, NC; 2Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.

    Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…
  • 2018 American Transplant Congress

    Use of Cyclin-Dependent Kinase Inhibitors to Reduce Gammaherpesvirus Reactivation

    J. Hazleton,1 L. van Dyk.2

    1Pediatrics, Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO; 2Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.

    Infection with the gammaherpesvirus EBV occurs in over 90% of humans and leads to lifelong viral latency with intermittent reactivation that is typically controlled through…
  • 2018 American Transplant Congress

    Evaluation of Drug Action on IgM Memory B Cell Survival and Growth In Vitro; -Application for Individualized Immunosuppression after Kidney Transplants-

    Y. Matsuda,1 K. Takahashi,1 R. Imamura,2 N. Nonomura,2 Y. Yuzawa.1

    1Nephrology, Fujita Health University, Toyoake, Aichi, Japan; 2Urology, Osaka University, Suita, Osaka, Japan.

    (Background)Recently, the establishment of early diagnosis and treatment methods for antibody-mediated rejection (ABMR) has garnered much attention.Strong immunosuppression including desensitization is accompanied by severe side…
  • 2018 American Transplant Congress

    Approaches to Prevention of Antibody Rebound after HLA Sensitization in a Mouse Model

    I. Kim, G. Wu, N-.N. Chai, A. Klein, S. Jordan.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

    Purpose: Control of donor specific antibodies (DSA) is critical for prevention of antibody mediated rejection (ABMR). Removal of DSAs with PLEX often results in significant…
  • 2018 American Transplant Congress

    In-Vivo Visualization of Regulatory B Cells Reveals Ag-Dependent T Cell Interactions That Suppress Subsequent T Cell:DC Interactions

    K. Mohib, A. Cherukuri, Y. Zhou, R. David.

    Starzl Transplantation Institute, Univ. of Pittsburgh, Pittsburgh, PA.

    We showed that regulatory B cells (Bregs) promote long-term islet allograft survival. Using mice with a novel inducible B cell-specific deletion of IL-10 (IL-10fl/flXhCD20TAM-Cre) we…
  • 2018 American Transplant Congress

    Further In Vivo and In Vitro Evidence That Anti-CD40 MABS Do Not Induce Thromboembolism

    T. Rubic-Schneider, B. Christen, N. Runser Loll, D. Garcia, E. Erard, T. Flandre, B. Cochin de Billy, S. Nock, S. Côté, J. Rush, P. Ulrich.

    Novartis Institutes for Biomedical Research, Basel, Switzerland.

    Clinical trials with non-silenced anti-CD40L (anti-CD154) monoclonal antibodies (mAb) in patients with systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP) were halted after unexpected…
  • 2018 American Transplant Congress

    Postoperative Immunological Profiles of Adult ABO-Incompatible Living Donor Liver Transplant Recipients

    T-.J. Wu, Y-.C. Wang, C-.H. Cheng, T-.H. Wu, C-.F. Lee, H. Chou, K-.M. Chan, W-.C. Lee.

    Division of Liver and Transplantation Surgery, Department of General Surgery, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan, Taiwan.

    Background: Adult ABO-incompatible (ABOi) living donor liver transplantation has been performed for acute liver failure or end stage liver diseases when deceased liver allografts or…
  • 2017 American Transplant Congress

    Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction.

    D. Nayak,1 K. Garcia,2 P. Pirrotte,2 R. Hachem,3 R. Bremner,1 M. Smith,1 T. Mohanakumar.1

    1Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ; 2Translational Genomics Research Institute, Phoenix, AZ; 3Washington University, St. Louis, MO

    Background: Development of chronic lung allograft dysfunction (CLAD) limits long-term success from lung transplantation (LTx). Elicitation of de novo antibody (Ab) to mismatched donor HLA…
  • 2017 American Transplant Congress

    Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.

    T. Hirose, D. Iwami, K. Hotta, H. Sasaki, H. Higuchi, N. Shinohara.

    Urology, Hokkaido University, Sapporo, Japan

    [Introduction] Administration of rituximab to ABO-incompatible kidney transplant (ABOi-KTx) recipients is recognized as effective and safe. A single dose of 375 mg/m2 rituximab is generally…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 35
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences